John Lusher  The Social Buzz Lab(@JohnLusher) 's Twitter Profile Photo

Are you the type to lie in bed at night dwelling on conversations from the day? It’s a common practice, but this interpretation is — in most cases — likely incorrect. buff.ly/3VOhmnd

Are you the type to lie in bed at night dwelling on conversations from the day?  It’s a common practice, but this interpretation is — in most cases — likely incorrect. buff.ly/3VOhmnd
account_circle
NICE(@NICEComms) 's Twitter Profile Photo

Children and young people aged between 6-17 years with Bardet-Biedl syndrome will soon be able to start a new treatment option.

Our final highly specialised technologies guidance recommending setmelanotide published today.

Learn more: nice.org.uk/guidance/hst31…

Children and young people aged between 6-17 years with Bardet-Biedl syndrome will soon be able to start a new treatment option. 

Our final highly specialised technologies guidance recommending setmelanotide published today.

Learn more: nice.org.uk/guidance/hst31… 

#NICENews
account_circle
NICE(@NICEComms) 's Twitter Profile Photo

Five devices to diagnose a sleep condition seriously harming the health of an estimated 2.5 million adults have been recommended in draft guidance.

They are considered less invasive, more comfortable to wear and easier to use.

Learn more: nice.org.uk/news/article/h…

Five devices to diagnose a sleep condition seriously harming the health of an estimated 2.5 million adults have been recommended in draft guidance.

They are considered less invasive, more comfortable to wear and easier to use.

Learn more: nice.org.uk/news/article/h… #NICENews
account_circle
NICE(@NICEComms) 's Twitter Profile Photo

Children and young adults could benefit after a personalised immunotherapy to treat an aggressive form of blood cancer was recommended for routine use.

Tisagenlecleucel was previously available via the Cancer Drugs Fund.

Learn more: nice.org.uk/guidance/ta975…

Children and young adults could benefit after a personalised immunotherapy to treat an aggressive form of blood cancer was recommended for routine use.

Tisagenlecleucel was previously available via the Cancer Drugs Fund.

Learn more: nice.org.uk/guidance/ta975… #NICENews
account_circle
NICE(@NICEComms) 's Twitter Profile Photo

People with the rare heart condition transthyretin amyloidosis cardiomyopathy could be offered the once-a-day tablet tafamidis.

Our final draft guidance recommends the treatment following a new price deal agreed with the company.

Learn more: nice.org.uk/guidance/gid-t…

People with the rare heart condition transthyretin amyloidosis cardiomyopathy could be offered the once-a-day tablet tafamidis.

Our final draft guidance recommends the treatment following a new price deal agreed with the company.

Learn more: nice.org.uk/guidance/gid-t… #NICENews
account_circle
NICE(@NICEComms) 's Twitter Profile Photo

Thousands of people with haemolytic anaemia caused by sickle cell disease will be able to access new treatment voxelotor from today.

Our committee has recommended the daily tablets as an option in final draft guidance.

Learn more: nice.org.uk/news/article/i…

Thousands of people with haemolytic anaemia caused by sickle cell disease will be able to access new treatment voxelotor from today.

Our committee has recommended the daily tablets as an option in final draft guidance. 

Learn more: nice.org.uk/news/article/i…

#NICENews
account_circle
NICE(@NICEComms) 's Twitter Profile Photo

People with acute myeloid leukaemia with an IDH1 R132 mutation who cannot have standard intensive induction chemotherapy could be offered a new daily tablet.

Ivosidenib is recommended in final draft guidance with azacitidine.

Learn more: nice.org.uk/guidance/gid-t…

People with acute myeloid leukaemia with an IDH1 R132 mutation who cannot have standard intensive induction chemotherapy could be offered a new daily tablet.

Ivosidenib is recommended in final draft guidance with azacitidine.

Learn more: nice.org.uk/guidance/gid-t… #NICENews
account_circle
NICE(@NICEComms) 's Twitter Profile Photo

People at high risk of severe COVID-19 may benefit after final guidance recommending remdesivir was issued today.

The antiviral medicine is given as an infusion through a drip, once a day for 3 days.

Learn more: nice.org.uk/guidance/ta971…

People at high risk of severe COVID-19 may benefit after final guidance recommending remdesivir was issued today.

The antiviral medicine is given as an infusion through a drip, once a day for 3 days.

Learn more: nice.org.uk/guidance/ta971…

#NICENews
account_circle
NICE(@NICEComms) 's Twitter Profile Photo

People who suffer from chronic or episodic migraines could benefit from the first oral treatment option recommended for the conditions.

Atogepant can be offered on the NHS in England to prevent migraine attacks.

Learn more: nice.org.uk/guidance/ta973…

People who suffer from chronic or episodic migraines could benefit from the first oral treatment option recommended for the conditions. 

Atogepant can be offered on the NHS in England to prevent migraine attacks.

Learn more: nice.org.uk/guidance/ta973… #NICENews
account_circle
NICE(@NICEComms) 's Twitter Profile Photo

Children and teenagers could benefit after a new targeted combination treatment for a rare, aggressive form of brain cancer was recommended today.

Find out more about how dabrafenib with trametinib works: nice.org.uk/News/Article/c…

Children and teenagers could benefit after a new targeted combination treatment for a rare, aggressive form of brain cancer was recommended today.

Find out more about how dabrafenib with trametinib works: nice.org.uk/News/Article/c…

#NICENews
account_circle
NICE(@NICEComms) 's Twitter Profile Photo

People with Hodgkin lymphoma who have had at least 2 previous treatments and cannot have a stem cell transplant can now benefit from a new treatment option.

Pembrolizumab will soon be available in the NHS in England.

Learn more: nice.org.uk/guidance/ta968…

People with Hodgkin lymphoma who have had at least 2 previous treatments and cannot have a stem cell transplant can now benefit from a new treatment option.

Pembrolizumab will soon be available in the NHS in England.

Learn more: nice.org.uk/guidance/ta968…

#NICENews
account_circle
NICE(@NICEComms) 's Twitter Profile Photo

People with multiple myeloma whose cancer is not responding to treatment could be offered a new triple drug combination.

Selinexor is taken as a tablet and helps to stop myeloma cells from multiplying.

Learn more: nice.org.uk/guidance/gid-t…

People with multiple myeloma whose cancer is not responding to treatment could be offered a new triple drug combination.

Selinexor is taken as a tablet and helps to stop myeloma cells from multiplying.

Learn more: nice.org.uk/guidance/gid-t… 

#NICENews
account_circle